Finance

Lists
BIOCON:NSE
Biocon Ltd
350,55 INR
-0,41%
(-1,45) 1D
16 ოქტ, 13:41:40 GMT+5:30  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for BIOCON...
Open
352,60 INR
High
353,00 INR
Low
348,00 INR
Mkt. cap
570,99 მლრ.
Avg. vol.
2,97 მლნ.
Volume
1,06 მლნ.
Dividend
0,14%
Quarterly dividend
0,12 INR
Ex-dividend date
3 ივლ. 2026
P/E ratio
103,78
52-wk high
447,15 INR
52-wk low
337,70 INR
EPS
3,38 INR
Shares outstanding
600,00 მლნ.
No. of employees
16 ათ.
Open
352,60 INR
High
353,00 INR
Low
348,00 INR
Mkt. cap
570,99 მლრ.
Avg. vol.
2,97 მლნ.
Volume
1,06 მლნ.
Dividend
0,14%
Quarterly dividend
0,12 INR
Ex-dividend date
3 ივლ. 2026
P/E ratio
103,78
52-wk high
447,15 INR
52-wk low
337,70 INR
EPS
3,38 INR
Shares outstanding
600,00 მლნ.
No. of employees
16 ათ.
News stories
From web sources and news partners
Profile
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, with U.S. headquarters in Bridgewater, New Jersey. Founded by Kiran Mazumdar-Shaw in 1978 as a partner to the Irish brewing enzyme manufacturer Biocon Biochemicals Ltd., the company manufactures generic active pharmaceutical ingredients that are sold in approximately 120 countries, including the United States and Europe. It also manufactures novel biologics, and branded drugs such as biosimilar insulins and antibodies for the Indian domestic market. Biocon's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. Biocon's formulations for the Indian market include metabolics, oncology, immunotherapy, and nephrology products. Some of Biocon's key brands in India include INSUGEN, BASALOG, BIOMAb EGFR, BLISTO, CANMAb, Evertor, TACROGRAF, ALZUMAb and KRABEVA. Syngene International Limited is a publicly listed subsidiary of Biocon, operating in the contract research and development organization. Wikipedia
About Biocon Ltd
CEOShreehas P Tambe
Employees16,4 ათ.
Founded29 ნოე. 1978
Headquartersბენგალურუ, კარნატაკა, ინდოეთი
Sector-
Websitebiocon.com
Last report
6 აგვ. 2026
Fiscal period
Q1 2027
0,95 INR / 1,09 INR
-12,68%miss
Revenue / Est. (INR)
43,36 მლრდ. / 44,74 მლრდ.
-3,08%miss
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
42,96 მლრდ.
41,73 მლრდ.
45,17 მლრდ.
43,36 მლრდ.
Cost of goods sold
17,72 მლრდ.
13,39 მლრდ.
23,69 მლრდ.
14,68 მლრდ.
Cost of revenue
17,72 მლრდ.
13,39 მლრდ.
23,69 მლრდ.
14,68 მლრდ.
Research and development expenses
-132,00 მლნ.
-531,00 მლნ.
-128,00 მლნ.
-16,00 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
9,59 მლრდ.
8,75 მლრდ.
13,28 მლრდ.
9,16 მლრდ.
Operating expense
21,18 მლრდ.
25,16 მლრდ.
14,45 მლრდ.
25,69 მლრდ.
Total operating expenses
38,90 მლრდ.
38,55 მლრდ.
38,14 მლრდ.
40,36 მლრდ.
Operating income
4,05 მლრდ.
3,18 მლრდ.
7,03 მლრდ.
3,00 მლრდ.
Other non operating income
94,00 მლნ.
1,17 მლრდ.
-2,52 მლრდ.
545,00 მლნ.
EBT including unusual items
1,71 მლრდ.
-678,00 მლნ.
2,48 მლრდ.
1,28 მლრდ.
EBT excluding unusual items
1,23 მლრდ.
2,26 მლრდ.
1,80 მლრდ.
1,41 მლრდ.
Income tax expense
385,00 მლნ.
-160,00 მლნ.
489,00 მლნ.
-92,00 მლნ.
Effective tax rate
22,48%
23,60%
19,76%
-7,21%
Other operating expenses
6,72 მლრდ.
11,78 მლრდ.
-4,12 მლრდ.
11,07 მლრდ.
Net income
845,00 მლნ.
1,44 მლრდ.
1,26 მლრდ.
1,41 მლრდ.
Net profit margin
1,97%
3,45%
2,79%
3,25%
Earnings per share
0,72
2,74
1,27
0,95
Interest and investment income
235,00 მლნ.
-
1,15 მლრდ.
-
Interest expense
-2,72 მლრდ.
-2,10 მლრდ.
-2,06 მლრდ.
-2,13 მლრდ.
Net interest expenses
-2,49 მლრდ.
-2,10 მლრდ.
-906,00 მლნ.
-2,13 მლრდ.
Depreciation and amortization charges
4,73 მლრდ.
5,15 მლრდ.
5,13 მლრდ.
5,47 მლრდ.
EBITDA
8,69 მლრდ.
7,13 მლრდ.
11,62 მლრდ.
7,59 მლრდ.
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google აპები